Cardiac safety and antitumor activity of doxorubicin and taxol followed by weekly taxol (AT&amp;T) when herceptin is initiated with AT or with T alone in women with HER2-positive advanced breast cancer

Giannì, L.; Eiermann, W.; Borquez, D.; Albanell, Joan; Molina, R.; Vanhauwere, Bart; Baselga, José

doi:10.1016/s0959-8049(01)81190-4

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A pilot study has been performed to investigate the cardiac safety and pharmacology of trastuzumab plus doxorubicin and paclitaxel followed by weekly paclitaxel [28].…”

Section: ‫ء‬mentioning

confidence: 99%

Clinical Cardiac Tolerability of Trastuzumab

Perez

Rodeheffer

2004

JCO

261

149

View full text Add to dashboard Cite

show abstract

“…A pilot study has been performed to investigate the cardiac safety and pharmacology of trastuzumab plus doxorubicin and paclitaxel followed by weekly paclitaxel [28].…”

Section: ‫ء‬mentioning

confidence: 99%

Clinical Cardiac Tolerability of Trastuzumab

Perez

Rodeheffer

2004

JCO

261

149

View full text Add to dashboard Cite

show abstract

“…In 60 patients with evidence of cardiac dysfunction, including 25 patients with previous anthracycline exposure, Fuchs and colleagues found only faint membrane staining in less than 10% of cardiac biopsies and no evidence of gene amplification by FISH (Fuchs et al 2001). It also seems unlikely that trastuzumab alters the pharmacokinetic properties of anthracyclines and one study has failed to demonstrate any difference in the pharmacokinetics of doxorubicin when it was administered before or after trastuzumab (Gianni et al 2001).…”

Section: Clinical Safety Of Trastuzumabmentioning

confidence: 99%

The development and clinical use of trastuzumab (Herceptin).

Harries¹,

Smith²

2002

Endocrine-Related Cancer

172

View full text Add to dashboard Cite

HER-2 is a member of the c-erbB family of receptor tyrosine kinases and is overexpressed by 20-30% of human breast cancers. HER-2 overexpression is an independent adverse prognostic factor and may also predict for response to both chemotherapy and endocrine agents. Trastuzumab is a humanised monoclonal antibody that binds with high affinity to the extracellular domain of HER-2. In HER-2-overexpressing preclinical models trastuzumab has been shown to have a marked antiproliferative effect and demonstrates synergy with a number of cytotoxic drugs. Several phase II and phase III clinical trials have now been performed in patients with advanced breast cancer that overexpress HER-2. Trastuzumab was initially shown to be active and well tolerated as a single agent in heavily pretreated women. Subsequently, studies of first-line treatment for metastatic breast cancer have demonstrated an improvement in survival for trastuzumab when used in combination with either paclitaxel or an anthracycline-cyclophosphamide regimen compared with chemotherapy alone. Unexpectedly, the combination of trastuzumab and the anthracycline-containing regimen was associated with a significant incidence of cardiac dysfunction. The benefit of trastuzumab is generally confined to patients whose tumours have gene amplification as detected by fluorescence in situ hybridisation (FISH) and this is tightly associated with immunohistochemical (IHC) staining at the highest (3 + ) level. A small number of patients have IHC 2 + tumours together with FISH evidence of gene amplification and may also derive benefit from treatment. Trastuzumab has also been shown to be effective when used as first-line monotherapy for advanced breast cancer. Trials to date have employed trastuzumab in a weekly schedule, but there is emerging evidence that a three-weekly regimen may be as effective. Trastuzumab has shown encouraging activity when used with other agents including docetaxel and vinorelbine. The combination of trastuzumab, docetaxel, and platinum salts also appears to be very active. The role of trastuzumab as adjuvant therapy for early breast cancer is being tested in a number of large randomised trials.

show abstract

“…Substudies of data concordance between echocardiography and radionuclidebased testing and of the potential role of early indicators of cardiac injury in predicting clinical outcomes are being developed. Of some reassurance, since these adjuvant studies were initiated, are the preliminary data regarding the safety of anthracyclines, administered concurrently with trastuzumab and paclitaxel, if the number of cycles is limited as reported by Gianni et al [27] at ASCO 2001.…”

Section: Integration Of New Therapies Into Adjuvant Treatment Regimensmentioning

confidence: 99%

The role of adjuvant monoclonal antibody therapy for breast cancer: Rationale and new studies

Perez

2001

Curr Oncol Rep

View full text Add to dashboard Cite

HER2 is a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases and is involved in the growth, invasion, metastasis, and prognosis of breast cancer. The rationale for prospective trials evaluating the role of anti-HER2 monoclonal antibody therapy for patients with high-risk HER2-positive resected breast cancer is based on several factors. These include 1) the relative and absolute poor prognosis of patients with node-positive, HER2-positive breast cancer; 2) the emerging data of potential importance concerning anthracyclines as a component of adjuvant therapy for patients with HER2-positive breast cancer; 3) the role of taxanes in the management of patients with HER2-positive metastatic breast cancer; and 4) the feasibility and efficacy of molecularly targeted anti-HER2 monoclonal antibody treatment alone or in combination with chemotherapy for patients with advanced breast cancer.

show abstract

Cardiac safety and antitumor activity of doxorubicin and taxol followed by weekly taxol (AT&T) when herceptin is initiated with AT or with T alone in women with HER2-positive advanced breast cancer

Cited by 6 publications

References 0 publications

Clinical Cardiac Tolerability of Trastuzumab

Clinical Cardiac Tolerability of Trastuzumab

The development and clinical use of trastuzumab (Herceptin).

The role of adjuvant monoclonal antibody therapy for breast cancer: Rationale and new studies

Contact Info

Product

Resources

About